Document is current
Any future updates will be listed below
-
Authors
Esquenazi, Alberto https://orcid.org/0000-0003-0698-6424
Wein, Theodore H. https://orcid.org/0000-0002-8994-8628
Verduzco-Gutierrez, Monica https://orcid.org/0000-0003-0964-5908
Ayyoub, Ziyad https://orcid.org/0009-0009-6480-5418
Page, Simon https://orcid.org/0000-0002-7225-3774
Harding, Sarah https://orcid.org/0009-0007-2818-105X
Maisonobe, Pascal https://orcid.org/0009-0004-3469-7261
Beneteau, Mathieu https://orcid.org/0009-0001-6741-1328
Patel, Atul https://orcid.org/0000-0003-2765-7953
,
Sequeira, Keith
Wein, Theodore
Sangani, Masoud
Blanc, Pierre
Cassoudesalle, Hélène
Amauger, Emmanuel
Gallien, Philippe
Pérennou, Dominic
Luauté, Jacques
Ghassan, Ido
Gasq, David
Ferrapie, Anne-Laure
Horobeti, Isner- Marie-Eve
Gross, Raphaël
Butet, Simon
Corre, Tanguy Le
Angioni, Florence
Honore, Thibaud
Edgley, Steven
Stilling, Joan
Bowers, David
Liow, Kore
Charles, David
Roy, Vivian
Zorowitz, Richard
Fusco, Heidi
Goodfriend, Karin
Hedera, Peter
Dashtipour, Khashayar
Arac, Ahmet
Stevens, James
Burris, Joseph
Bhatia, Periminder
Truong, Daniel
Bethoux, Francois
Gul, Fatma
McAllister, Peter
Dabrowski, Edward
Sherman, Scott
Hatch, Anne
Vu, Tuan
Wainberg, Michael
Weiss, Richard
Zhou, Xiaohua
Ho, Johnathan
Hasbani, Mayer Joshua
Byron Milton III, S
Chen, Yuxi
Deeb, Wissam
Balsiger, Robert
Copeland, Brian
Vandenberg, Jonathan
Christian, Asare
Romanoski, Natasha
Munin, Michael
Patel, Nirav
Linsenmeyer, Mark
Ivanhoe, Cindy Beth
Evidente, Virgilio
Mayadev, Angeli
Sundaram, Bharathy
Espinosa, Patricio
Spinner, Warren
McCarthy, Marissa
Saulino, Michael
Ramos, Edwardo
Edward, Dabrowski
Sierens, Harmony
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04936542 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity
https://doi.org/10.1007/s12325-026-03635-y
AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol
https://doi.org/10.1007/s12325-021-01896-3
-
Funding
Funding for this research was provided by:
Ipsen
- License Information
-
More Information
Article History
Received: 2 April 2026
Accepted: 7 May 2026
First Online: 20 May 2026
Declarations
:
: Alberto Esquenazi: Consulting: Allergan and Ipsen; Research grants: Allergan, Bristol Myers Squibb, and Ipsen. Theodore H. Wein: Research: Ipsen, AbbVie, Canadian Institutes of Health Research/Eurospocnet; Consulting, honoraria/payment and travel support: AbbVie, Ipsen; Advisory Boards: Ipsen; Data Safety Monitoring Board: Pacira Biosciences, PharmaZzz. Monica Verduzco-Gutierrez: Consulting: AbbVie, Ipsen, Merz, Piramal, Revance. Research grants: Ipsen; Data Safety Monitoring Board: Pacira Biosciences. Ziyad Ayyoub: Consulting: honoraria from AbbVie, Ipsen, and Revance Therapeutics, Inc. Simon Page: Employee and shareholder of Ipsen. Sarah Harding: Employee and shareholder of Ipsen. Pascal Maisonobe: Employee of Ipsen. Mathieu Beneteau: Employee of Ipsen. Atul Patel: Consulting: AbbVie, Ipsen, and Revance; Speaker’s Bureau: AbbVie and Ipsen; Research: (to institution) AbbVie, Ipsen, and Pacira; Treasurer (during the study)/Vice President (at the time of writing) of the American Academy of Physical Medicine and Rehabilitation.
: The study was conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines and International Conference on Harmonisation Good Clinical Practice Guidelines. All patients provided written informed consent. The protocol and informed consent forms were reviewed and approved by the sponsor, the central ethics committee (Advarra), and by the applicable institutional review boards/ethical committees at participating sites with respect to scientific content and compliance with applicable regulations for research and humans (Table S1).
